Ranibizumab vs. pegaptanib: a cost-effectiveness study?

被引：0
作者：
Viroj Wiwanitkit
机构：
[1] Wiwanitkit House,
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2010年 / 248卷
关键词：
Public Health; Indirect Cost; Photodynamic Therapy; Comparative Evaluation; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1675 / 1675
相关论文
共 8 条
[1]  
Hernández-Pastor LJ(2010)Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol. 248 467-476
[2]  
Ortega A(2008)Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration Clin Ther. 30 2436-2451
[3]  
García-Layana A(undefined)undefined undefined undefined undefined-undefined
[4]  
Giráldez J(undefined)undefined undefined undefined undefined-undefined
[5]  
Hernández-Pastor LJ(undefined)undefined undefined undefined undefined-undefined
[6]  
Ortega A(undefined)undefined undefined undefined undefined-undefined
[7]  
García-Layana A(undefined)undefined undefined undefined undefined-undefined
[8]  
Giráldez J(undefined)undefined undefined undefined undefined-undefined
1